中国实验血液学杂志最新文献

{"title":"[Correlation Analysis between <i>STING</i> Promoter Polymorphism and Susceptibility to Infection after Chemotherapy for Multiple Myeloma].","authors":"Zhao-Ping Huang, Can-Hua Yang","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.042","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.042","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the correlation between the stimulator of interferon genes (<i>STING</i> ) promoter polymorphism and the susceptibility to infection after chemotherapy for multiple myeloma.</p><p><strong>Methods: </strong>A total of 102 patients who had undergone chemotherapy for multiple myeloma in our hospital from January 2016 to July 2022 were selected. Depending on the presence or absence of infection after chemotherapy, the enrolled patients were divided into infection group (53 cases) and non-infection group (49 cases). The infection sites and distribution characteristics of pathogenic bacteria of the infection group were analyzed. The genotype distribution of <i>STING</i> gene promoter rs587777609 was compared between the two groups, and the risk factors of infection after chemotherapy for multiple myeloma were analyzed.</p><p><strong>Results: </strong>For infection site, digestive system, respiratory system, urinary system, skin and mucous membranes accounted for 43.40%, 26.42%, 20.75%, and 9.43%, respectively. For pathogenic bacteria, Gram-negative bacteria, Gram-positive bacteria and fungi accounted for 57.14%, 26.98%, and 15.87%, respectively. The CC genotype frequency of <i>STING</i> gene rs587777609 locus in the infection group was lower than that in the non-infection group, while the TT genotype frequency was higher than that in the non-infection group (<i>P</i> < 0.05). The proportions of patients with diabetes, chronic obstructive pulmonary disease, renal insufficiency, serum albumin level< 35 g/L, ISS stage III, mechanical ventilation, and indwelling catheter in the infection group were higher than those in the non-infection group (<i>P</i> < 0.05). Multivariate logistic regression analysis showed that diabetes (<i>OR</i> =1.992), serum albumin level< 35 g/L (<i>OR</i> =2.782), ISS stage III (<i>OR</i> =2.707), mechanical ventilation (<i>OR</i> =3.031), and TT genotype (<i>OR</i> =2.401) were risk factors of infection after chemotherapy for multiple myeloma (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>There is a correlation between <i>STING</i> promoter polymorphism and the susceptibility to infection after chemotherapy for multiple myeloma, and patients with TT genotype have a higher risk of infection.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Target Selection of CAR-T Therapy in Acute Myeloid Leukemia--Review].","authors":"Ruo-Nan Shao, Hong-Le Xin, Xiao-Feng Shi","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.049","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.049","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR) T cell therapy, one of the most promising tumor treatments, combines the targeted recognition of antigen and antibody with the killing effect of T cells. CAR-T has shown a strong therapeutic effect in lymphoid tumors and been applied in clinical practice. However, in the treatment of acute myeloid leukemia (AML), no effective and specific target like CD19 in lymphoid tumors has been found. Therefore, the key research direction is to try multiple probabilities and use optimization strategies to enhance efficacy and reduce toxicity. This review introduces the latest research progress of AML targets in CAR-T therapy in recent years, analyzes the related problems that need to be solved at present, and summarizes the optimization construction strategies mentioned in the research. Hope it can provide reference for related research and clinical application of related product.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Research Progress in the Diagnosis and Treatment of Primary Intestinal Diffuse Large B-cell Lymphoma--Review].","authors":"Xiao-Jun Chen, Su-Xia Lin, Yan-Quan Liu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.047","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.047","url":null,"abstract":"<p><p>Primary intestinal diffuse large B-cell lymphoma (PI-DLBCL) is clinically rare, but in recent years, with the gradual maturity of pathology and molecular biology technology, its incidence rate and diagnosis rate have also increased. Due to the lack of specificity of the clinical symptoms of PI-DLBCL, it is easy to misdiagnose and miss the diagnosis, and there is no consensus on the best treatment of PI-DLBCL in clinical practice. Therefore, by retrieving the latest literature at home and abroad, this review systematically discusses the pathogenesis, clinical manifestations, diagnostic criteria, treatment and prognosis of PI-DLBCL, in order to improve the understanding of rare PI-DLBCL in hematology and oncology, and provide reference for basic research and clinical diagnosis and treatment of PI-DLBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Significance of Serum ADA Combined with GLB, CREA, β₂-MG and HGB in Newly Diagnosed Multiple Myeloma].","authors":"Han Qian, Hong-Ling Yuan, Ting Zhang, Yu-Wei Yang, Jia-Fu Feng","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.019","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.019","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role of serum adenosine deaminase (ADA) combined with globulin (GLB), creatinine (CREA), β₂-microglobulin (β₂-MG) and hemoglobin (HGB) in the initial screening of multiple myeloma (MM), in order to reduce missed diagnosis and misdiagnosis of MM.</p><p><strong>Methods: </strong>A retrospective analysis was performed on 62 newly diagnosed multiple myeloma (NDMM) patients who were admitted to the Department of Hematology of the First Affiliated Hospital of Chengdu Medical College from April 2018 to December 2021, and 33 patients with benign hematologic diseases and 30 healthy subjects were selected as the control group. The expression of ADA in pan-cancer was analyzed using TCGA and GTEx databases. The general data and laboratory indicators of the subjects were collected, and the differences of ADA activity and other laboratory indicators in each group were compared. The relationship between serum ADA activity and clinical data of NDMM patients was analyzed. The changes of ADA activity before and after chemotherapy in NDMM patients and the differences of ADA activity in NDMM patients with different DS and ISS stages were compared. Multivariate logistic regression was used to analyze the risk factors of NDMM. The receiver operating characteristic(ROC) curve was used to evaluate the diagnostic efficacy of ADA and other laboratory indicators in MM. Bioinformatics method was used to analyze the co-expression networks and enrichment pathways of ADA.</p><p><strong>Results: </strong>ADA level was significantly upregulated in tissues of 14 types of cancer in TCGA database, and ADA was highly expressed in 11 types of cancer in TCGA combined with GTEx databases. The serum levels of ADA, GLB, uric acid (UA), cystatin C (CysC) and β₂-MG in the NDMM group were significantly higher than those in benign hematologic disease group and healthy control group ( <i>P</i> < 0.05), while the levels of ALB and the value of albumin to globulin ratio (A∶G) in the NDMM group were significantly lower than those in the other two groups ( <i>P</i> < 0.001). There were significant differences in DS stage (<i>P</i> =0.036), ISS stage (<i>P</i> =0.019) and the levels of CREA (<i>P</i> =0.036), UA (<i>P</i> =0.034), β₂-MG (<i>P</i> =0.019) in NDMM patients with different ADA activity levels. After primary chemotherapy, ADA activity and β₂-MG concentration were decreased in NDMM patients ( <i>P</i> < 0.01). The comparison results of patients in different stages showed that ADA activity of patients in DS stage I+II was significantly lower than that of patients in DS stage III (<i>P</i> <0.05), and ADA activity of patiens in ISS stage I+II was significantly lower than that of patients in ISS stage III ( <i>P</i> < 0.01). Multivariate logistic regression analysis showed that increased GLB, increased ADA activity, increased CREA, increased β₂-MG and decreased HGB were indep","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Application Study of Voriconazole and Its Metabolites Concentration Monitoring in Allogeneic Hematopoietic Stem Cell Transplantation Patients].","authors":"Hong-Chun Wang, Lei Wang, Meng Li, Lei Shi, Hui-Hui Sun, Hong-Xing Liu, Hong-Ling Ou","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.045","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.045","url":null,"abstract":"<p><strong>Objective: </strong>To explore the application value of simultaneous monitoring of voriconazole (VRCZ) and voriconazole N-oxide (VNO) in efficacy and safety of VRCZ in the prevention and treatment of fungal infections in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients before engraftment (i.e., days +1 to +30 after transplantation).</p><p><strong>Methods: </strong>The influencing factors of VRCZ, VNO concentration and MR (C_VNO/C_VRCZ) and the difference of VRCZ in the prevention and treatment of fungal infection and liver and kidney injury were analyzed. The receiver operating characteristic curve (ROC) was used to analyze the differences (the corresponding to the maximum of the Youden index on the curve was set as the cut-off value) to confirm the critical value.</p><p><strong>Results: </strong>The factors affecting VRCZ concentration (C_VRCZ), VNO concentration (C_VNO) and MR were patient weight, VRCZ daily dose, and transplantation type (all <i>P</i> < 0.05). C_VRCZ and C_VNO in the effective group were higher than those in the ineffective group (<i>P</i> < 0.001), the opposite of MR (<i>P</i> < 0.001); the liver and renal injury group had lower MR than the normal group (<i>P</i> < 0.05). ROC showed that C_VRCZ, C _VNO and MR had important value in predicting VRCZ in the prevention and treatment of invasive fungal infections in allo-HSCT patients before engraftment, and their cutoff of concentrations were 0.95 μg/ml, 1.35 μg/ml and 1.645, respectively (AUC: 0.9677, 0.7634, 0.9564). C_VRCZ and MR can assist in indicating liver ［cutoff values: 0.65 μg/ml, 1.96 (AUC: 0.5971, 0.6663)］ and renal injury ［cutoff values: 0.95 μg/ml, 1.705 (AUC: 0.6039, 0.6164)］.</p><p><strong>Conclusion: </strong>The great value of simultaneous monitoring of VRCZ, VNO and MR can predict in the efficacy and safety of VRCZ in allo-HSCT patients before engraftment. The prediction accuracy of C_VRCZ was higher than that of MR, followed by that of C_VNO. Increased C_VRCZ and decreased MR increase the risk of liver and kidney injury.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of Mild SARS-CoV-2 Infection on Hematological Parameters and Suitability of Apheresis Platelets Donation in Blood Donors].","authors":"Shu-Ming Huang, Xiao-Mei Lin, Wei-Mei Jiang, Shu-Hua Ji, Shou Lin, Hong-Keng Lin, Cen Chen, Xiao-Ling Chu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.036","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.036","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of mild SARS-CoV-2 infection on hematological parameters of adult blood donors and the suitability of apheresis platelet donation, the changes of the hematological parameters in blood donors with mild infection of the SARS-CoV-2 Omicron variant strain were evaluated.</p><p><strong>Methods: </strong>Seventy-two blood donors with mild COVID-19 symptoms who donated consecutive apheresis platelets for 3 times from December 2022 to January 2023, 42 cases among which were included in the infection-positive group, and 30 cases in the suspected infection group. Forty-two donors un-vaccinated against SARS-CoV-2, un-infected, and donated three consecutive apheresis platelets from October to November 2022 were included in the control group. The changes of blood routine testing in the positive group and the suspected infection group were retrospectively compared before (Time1) and after (Time2 and Time3) the onset of symptoms, three consecutive times (Time1, Time2, Time3) in the control group by repeated measures analysis of variance. The Bayesian discriminant method was used to establish a discriminant equation to determine whether the recent infection of SARS-CoV-2 occurred or not.</p><p><strong>Results: </strong>Simple effect of the number times of tests in the positive and suspected infection groups was significant（ <i>F</i>_{infection-positive group}=6.98, <i>P</i> < 0.001, partial η²=0.79, <i>F</i>_{suspected infection group}=4.31, <i>P</i> < 0.001, partial η²=0.70）. The positive group and the suspected infection group had lower RBC, HCT, and HGB, and higher PLT and PCT at Time2 compared to Time1 and Time3(<i>P</i> < 0.05). The positive group and the suspected infection group showes RDW-CV and RDW-SD at Time3 higher than Time1 and Time2 (<i>P</i> < 0.001). The simple effect of the number times of tests in the control group was not significant ( <i>F</i>=0.96, <i>P</i> =0.55, partial η²=0.34). The difference of the whole blood count parameters in the control group for three times was not statistically significant (<i>P</i> >0.05). We established a discriminant equation to determine whether the recent infection of SARS-CoV-2 occurred or not. The equation had an eigenvalue of 0.22, a canonical correlation of 0.43 (χ²=27.81, <i>P</i> < 0.001), and an analysis accuracy of 72.9%.</p><p><strong>Conclusion: </strong>The hematological indicators of RBC, HCT, HGB, PLT, PCT, RDW-CV and RDW-SD in blood donors who had infected with mild COVID-19 showed dynamic changes. The discriminant equation for whether they are infected recently with COVID-19 has a high accuracy rate.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Features and Prognostic of Patients with Primary Central Nervous System Lymphoma].","authors":"Li-Tian Zhang, Cui-Cui Li, Qi-Qi Jin, Hao-Yun Jiang, Ning-Nin Yue, Peng-Yun Zeng, Ling-Ling Yue, Chong-Yang Wu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.011","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.011","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical features and prognosis of patients with primary central nervous system lymphoma（PCNSL）.</p><p><strong>Methods: </strong>A retrospective analysis was performed on the relationship between clinical features, treatment regimen and prognosis in 46 newly diagnosed patients with primary central nervous system lymphoma who were diagnosed and treated in The Second Hospital of Lanzhou University from January 2015 to September 2022. Fisher's exact probability method was used to analyze the differences in clinical data of different subgroups. Kaplan-Meier survival curve was used to analyze the overall survival rate and progression-free survival rate of patients with different treatments, and the factors influencing survival were analyzed.</p><p><strong>Results: </strong>Among 46 patients with PCNSL, which pathological type were diffuse large B-cell lymphoma（DLBCL）. There were 26(56.5%) cases of male and 20(43.5%) of female, with a median age of 54(17-71) years. In Hans subtypes, 14 cases (30.4%) of GCB subtype, 32 cases (69.6%) of non-GCB subtype. 32 cases (69.6%) of Ki-67≥80%. Among 36 patients who completed at least 2 cycles of treatment with follow-up data, the efficacy evaluation was as follows: overall response rate(ORR) was 63.9%, complete response(CR) rate was 47.2%, 17 cases of CR, 6 cases of PR. The 1-year progression-free survival rate and 1-year overall survival rate was 73.6% and 84.9%, respectively. The 2-year progression-free survival rate and 2-year overall survival rate was 52.2% and 68.9%, respectively. The ORR and CR rate of 17 patients treated with RMT regimen was 76.5% and 52.9% (9 cases CR and 4 cases PR), respectively. Univariate analysis of 3 groups of patients treated with RMT regimen, RM-BTKi regimen, and RM-TT regimen as first-line treament showed that deep brain infiltration was associated with adverse PFS(<i>P</i> =0.032), and treatment regimen was associated with adverse OS in PCNSL patients（<i>P</i> =0.025）.</p><p><strong>Conclusion: </strong>Different treatment modalities were independent prognosis predictors for OS, the deep brain infiltration of PCNSL is a poor predictive factor for PFS. Patients with relapse/refractory (R/R) PCNSL have a longer overall survival time because to the novel medication BTKi. They have strong toleration and therapeutic potential as a first-line therapy for high-risk patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Retrospective Study of R±DHAX Regimen versus R-CHOP Regimen First-Line Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma].","authors":"Wei-Ping Wei, Xian-Qiu Yu, Li-Xia Wang, Shuo Zhang, Xiao-Ming Fei","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.010","DOIUrl":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.010","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical efficacy and prognosis of Rituximab combined with DHAX and CHOP regimen in the first-line treatment of elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Methods: </strong>A total of 36 elderly patients with DLBCL who were admitted and treated with 3 of more courses of treatment from August 2011 to August 2021 were retrospectively analyzed, and they were divided into rituximab±DHAX (R±DHAX) regimen group (18 cases) and rituximab±CHOP (R-CHOP) regimen group (18 cases) according to the treatment plan, and clinical features, efficacy and survival of the patients were observed.</p><p><strong>Results: </strong>Compared with R-CHOP group, patients of the R±DHAX group were older, and had worse performance status and higher IPI score, the differences between two groups in age, ECOG score and IPI score were statistically significant ( <i>P</i> =0.005 <i>P</i> =0.018, <i>P</i> =0.035), but there were no significant differences beween two groups in gender, whether there were B symptoms, whether LDH was elevated, whether there was extranodal involvement, cell origin, bone marrow infiltration, and whether rituximab was combined ( <i>P</i> =0.738, <i>P</i> =1, <i>P</i> =0.315, <i>P</i> =0.305, <i>P</i> =0.413, <i>P</i> =0.177, <i>P</i> =0.711, <i>P</i> =0.229). The efficacy could be evaluated in 36 cases, including CR 14 (38.9%), PR 17 (47.2%), PD 5 (13.9%), and ORR of 86.1% (31/36). There were no statistically significant differences in CR［(27.8%（5/18） <i>vs</i> 50.0%（9/18）; <i>P</i> >0.05］ and PR ［44.4%（8/18） <i>vs</i> 50.0%（9/18）; <i>P</i> >0.05］ of R±DHAX group and R-CHOP group, there was statistically significant difference in ORR［72.2%（13/18） <i>vs</i> 100.0%（18/18）; <i>P</i> =0.045］ between two groups. The 1-year OS of R±DHAX group and R-CHOP group was (38.9±11.5%)% and (94.4±7.4%)%, respectively, 2-year OS was (16.7±8.8)% and (72.2±10.6)%, respectively, and the differences between two groups were statistically significant ( <i>P</i> =0.001, <i>P</i> =0.002). The median survival time in the R±DHAX group was 11 months(95%<i>CI</i> :8.9-13.1), and the median survival time in the R-CHOP group was not reached, and there was a statistically significant difference between the groups (<i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>For elderly DLBCL patients, R±DHAX may not be superior to R-CHOP in OS, and ECOG score, IPI score and age may affect the survival of elderly DLBCL patients. However, R±DHAX regimen is safe, tolerable and has a certain efficacy, which can be used as one of the clinical treatment options for elderly DLBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Study on Down-regulation of Interleukin-1β Secretion by Inhibiting ABCC1/MRP1 Transporter].","authors":"Yuan-Yuan Chen, Pei-Ting Ying, Wen-Wen Weng, Mei-Xin Fang, Jiang Li, Ze-Bin Luo, Ming Jia, Xiao-Ping Guo, Ling-Yan Zhang, Xiao-Jun Xu, Yong-Min Tang","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.040","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.040","url":null,"abstract":"<p><strong>Objective: </strong>To screen interleukin (IL)-1β secretion-related membrane transporters by macrophage experiment <i>in vitro</i> and conventional knockout mice.</p><p><strong>Methods: </strong>THP-1 cell line was differentiated to obtain human THP-1-derived macrophages, and the primary macrophages were obtained from human peripheral blood. <i>FVB</i> wild-type mice with the same sex and age were used as the controls of <i>MRP1</i> knockout mice. The macrophages in abdominal cavity and bone marrow of mice were cultivated. The cells were treated with ABCC1/MRP1, ABCG2/BCRP, ABCB1/P-gp, OATP1B1, and MATE transporter inhibitors, then stimulated by lipopolysaccharide and adenosine triphosphate. The secretion level of IL-1β was detected by ELISA, Western blot, and immunofluorescence.</p><p><strong>Results: </strong>After inhibiting ABCC1/MRP1 transporter, the secretion of IL-1β decreased significantly, while inhibition of the other 4 transporters had no effect. In animal experiment, the level of IL-1β secreted by macrophages in bone marrow of <i>MRP1</i> knockout mice was significantly lower than control group (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>ABCC1/MRP1 transporter is a newly discovered IL-1β secretion pathway, which is expected to become a new target for solving clinical problems such as cytokine release syndrome.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prognostic Factors Affecting Recurrence in Peripheral T-Cell Lymphoma Patients with Different HDAC Levels].","authors":"Ying-Xin Li, Yi-Dan Li, Pei Wang, Hui-Jie Jiao, Ying Li, Jing Zhang, Xian-Hua Yuan","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.012","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2024.03.012","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the distribution characteristics of prognostic factors affecting recurrence in peripheral T-cell lymphoma (PTCL) patients with different levels of histone deacetylase (HDAC) based on latent class analysis.</p><p><strong>Methods: </strong>112 PTCL patients who were treated in our hospital from September 2012 to September 2019 were selected and divided into recurrence group and non-recurrence group. The clinical data of the two groups of patients were compared. Multivariate logistic regression was used to analyze the risk factors for recurrence. Latent class analysis was used to compare the distribution characteristics of prognostic factors affecting recurrence between the high-risk group and the low-risk group.</p><p><strong>Results: </strong>There were 87 patients (77.68%) in recurrence group and 25 patients (22.32%) in non-recurrence group. The result of multivariate logistic regression showed that ECOG score ≥2, Ann Arbor stage III-IV, IPI score >2, bone marrow involvement, elevated serum β₂-microglobulin (β₂-MG), short-term efficacy not reaching complete remission (CR) or partial remission (PR), and the high expression of HDAC were all independent risk factors for recurrence in patients with PTCL (<i>P</i> <0.05). The recurrence rate of patients with high HDAC levels was significantly higher than that of patiens with low HDAC levels (<i>P</i> <0.05). The results of cluster analysis showed that the risk of recurrence was obviously clustered, and the patients could be divided into high recurrence risk group (HDAC＞5 points) and low recurrence risk group (HDAC≤5 points). The results of latent class analysis showed that patients with multiple risk factors account for a higher proportion in the high recurrence risk group, compared with the low recurrence risk group (<i>P</i> <0.05).</p><p><strong>Conclusion: </strong>There are differences in recurrence rates among PTCL patients with different HDAC levels and in distribution characteristics of risk factors between high recurrence risk and low recurrence risk groups.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}